Amyvid aids in the evaluation of adult patients with cognitive impairment who are being evaluated for Alzheimer’s Disease and other causes of cognitive decline.
Cardinal Health Nuclear Pharmacy Services business president John Rademacher said the company will efficiently and safely manufacture and distribute the imaging agent to the evaluate Alzheimer’s Disease and other causes of cognitive decline.
Amyvid binds to amyloid plaques, one of the necessary pathological features of Alzheimer’s Disease, and is detected using PET scan images of the brain.
Amyvid loses over half of its radioactivity every two hours, so the sites that manufacture it need to be located in close proximity to hospitals and health centers that will use it.